Sono-Tek Reports Sixth Consecutive Quarter of Revenue Over $5 Million and 150% Annual Increase in Medical Market Sales

Reuters
2025/10/14
Sono-Tek Reports Sixth Consecutive Quarter of Revenue Over $5 Million and 150% Annual Increase in Medical Market Sales

Sono-Tek Corporation reported financial results for the second quarter and first half of fiscal year 2026, ending August 31, 2025. The company recorded its sixth consecutive quarter with revenue exceeding $5 million and reported a 150% year-over-year increase in medical market sales. Fiscal first half net income rose 35%. The order backlog increased 50% sequentially. US/Canada sales decreased by $324,000, or 5% year-over-year, mainly due to lower demand in the clean energy sector. In Asia, sales increased by $647,000, or 74%, led by medical sales in China and alternative energy sales in Japan and South Korea. EMEA sales declined by $60,000, and Latin American sales decreased by $160,000, influenced by lower fluxing sales in Mexico. As of August 31, 2025, Sono-Tek held $10.6 million in cash, cash equivalents, and marketable securities, with no debt and stockholders' equity of $18.7 million. Capital expenditures for the first half of fiscal 2026 totaled $113,000. The company expects capital expenditures for the full fiscal year to reach approximately $300,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sono-Tek Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171520-25-000316), on October 14, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10